Agios drops tebapivat in sickle cell after Phase 2 falls short

July 21, 2026 7:00 AM

Agios Pharmaceuticals (NASDAQ: AGIO) said it will not advance tebapivat in sickle cell disease after a Phase 2 trial failed ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found